Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”

Detalles Bibliográficos
Autores principales: Aoki, Yuki, Kataoka, Yuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263251/
https://www.ncbi.nlm.nih.gov/pubmed/35812295
http://dx.doi.org/10.1016/j.ekir.2022.01.1075
_version_ 1784742688351846400
author Aoki, Yuki
Kataoka, Yuki
author_facet Aoki, Yuki
Kataoka, Yuki
author_sort Aoki, Yuki
collection PubMed
description
format Online
Article
Text
id pubmed-9263251
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-92632512022-07-09 Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial” Aoki, Yuki Kataoka, Yuki Kidney Int Rep Letter to the Editor Elsevier 2022-06-01 /pmc/articles/PMC9263251/ /pubmed/35812295 http://dx.doi.org/10.1016/j.ekir.2022.01.1075 Text en © 2022 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Aoki, Yuki
Kataoka, Yuki
Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
title Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
title_full Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
title_fullStr Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
title_full_unstemmed Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
title_short Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
title_sort letter regarding “dose-response of tenapanor in patients with hyperphosphatemia undergoing hemodialysis in japan—a phase 2 randomized trial”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263251/
https://www.ncbi.nlm.nih.gov/pubmed/35812295
http://dx.doi.org/10.1016/j.ekir.2022.01.1075
work_keys_str_mv AT aokiyuki letterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial
AT kataokayuki letterregardingdoseresponseoftenapanorinpatientswithhyperphosphatemiaundergoinghemodialysisinjapanaphase2randomizedtrial

Ejemplares similares